文献速递核素与放射性配体治疗肿瘤 PET/CT

治疗后4小时与24小时[177Lu]Lu-PSMA SPECT/CT及治疗前PSMA PET/CT在转移性去势抵抗性前列腺癌疾病评估中的比较

Comparison of Posttherapy 4- and 24-Hour [177Lu]Lu-PSMA SPECT/CT and Pretherapy PSMA PET/CT in Assessment of Disease in Men with Metastatic Castration-Resistant Prostate Cancer.
PubMed 文献 · J Nucl Med · 2024-12-03

这项前瞻性分析纳入23例接受[177Lu]Lu-PSMA-I&T治疗的转移性去势抵抗性前列腺癌患者,比较治疗后4小时与24小时[177Lu]Lu-PSMA SPECT/CT及基线[68Ga]Ga-PSMA-11 PET/CT在疾病评估中的表现。视觉分析显示3种影像方法疾病分布不变,4小时SPECT/CT与24小时SPECT/CT定量参数一致性在可接受范围内,剂量1与剂量2之间总肿瘤体积变化可预测前列腺特异性抗原无进展生存。作者认为4小时[177Lu]Lu-PSMA SPECT/CT是24小时显像的有前景替代方案,可提高患者便利性。

要点

  • 4小时与24小时[177Lu]Lu-PSMA SPECT/CT视觉分析疾病分布不变
  • 11例(52%)在4小时SPECT/CT上中位1个病灶未被识别,均小于2 cm
  • 剂量1与2之间总肿瘤体积变化可预测前列腺特异性抗原无进展生存

核心结论

  • 作者认为注射后4小时[177Lu]Lu-PSMA SPECT/CT似乎是有前景的24小时[177Lu]Lu-PSMA SPECT/CT替代方案,用于治疗反应评估,并提高患者便利性。

研究设计与样本

  • 前瞻性分析纳入23例诊断为转移性去势抵抗性前列腺癌并开始[177Lu]Lu-PSMA-I&T治疗的患者,2例因影像数据不完整被排除。
  • 治疗后SPECT/CT于第一剂后4小时和24小时及第二剂后4小时进行;基线[68Ga]Ga-PSMA-11 PET/CT与4小时、24小时[177Lu]Lu-PSMA SPECT/CT进行视觉和半定量分析。
  • 采用Bland-Altman图评估4小时与24小时扫描半定量参数的一致性,并将第一剂与第二剂后4小时[177Lu]Lu-PSMA SPECT/CT上总肿瘤体积变化与患者结局进行相关性分析。

主要发现

  • 所有患者均为转移性去势抵抗性前列腺癌且既往接受过雄激素受体通路抑制剂治疗,11例(52%)接受过紫杉烷类化疗。
  • 中位年龄78岁,中位前列腺特异性抗原水平54 ng/mL。
  • 视觉分析显示3种影像方法间疾病分布不变;11例(52%)在4小时[177Lu]Lu-PSMA SPECT/CT上中位1个病灶未被识别(与24小时SPECT/CT相比),所有漏诊病灶均小于2 cm。
  • 4小时与24小时SPECT/CT定量参数的平均差异和一致性在病灶数量、SUVmax和SUVmean方面处于可接受范围内,总肿瘤体积变异较大。
  • 第一剂与第二剂之间[177Lu]Lu-PSMA SPECT/CT上总肿瘤体积变化可预测前列腺特异性抗原无进展生存。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

[177Lu]Lu-prostate-specific membrane antigen (PSMA) is an effective treatment for metastatic castration-resistant prostate cancer (mCRPC). [177Lu]Lu-PSMA SPECT/CT 24 h after injection has shown potential as a response biomarker for [177Lu]Lu-PSMA therapy but is not convenient for patients. This study investigated 4-h [177Lu]Lu-PSMA SPECT/CT as an alternative to 24-h [177Lu]Lu-PSMA SPECT/CT for evaluation of treatment response. Methods: This prospective analysis enrolled 23 patients diagnosed with mCRPC commencing [177Lu]Lu-PSMA-I&T therapy. Two patients were excluded because of incomplete imaging data. Posttherapy SPECT/CT was performed at 4 and 24 h after the first dose and 4 h after the second dose. Baseline [68Ga]Ga-PSMA-11 PET/CT and 4- and 24-h [177Lu]Lu-PSMA SPECT/CT were analyzed both visually and semiquantitatively. Bland-Altman plots assessed agreement of semiquantitative parameters from the 4- and 24-h scans. Quantitative assessment of the change in the total tumor volume (TTV) on the 4-h [177Lu]Lu-PSMA SPECT/CT after the first and second doses was correlated to patient outcomes. Results: All patients had mCRPC previously treated with an androgen receptor pathway inhibitor, and 11 (52%) received prior taxane chemotherapy. Median age was 78 y, and median prostate-specific antigen level was 54 ng/mL. On visual analysis, disease distribution was unchanged among the 3 imaging methods. Eleven patients (52%) had a median of 1 lesion not identified on 4-h [177Lu]Lu-PSMA SPECT/CT compared with 24-h [177Lu]Lu-PSMA SPECT/CT. All missed lesions on the 4-h [177Lu]Lu SPECT/CT were smaller than 2 cm. Mean differences and agreement between 4- and 24-h SPECT/CT quantitative parameters were within acceptable bounds for lesion number, SUVmax, and SUVmean, with higher variation observed for TTV. The change in TTV between dose 1 and 2 [177Lu]Lu-PSMA SPECT/CT predicted prostate-specific antigen progression-free survival. Conclusion: [177Lu]Lu-PSMA SPECT/CT at 4 h after injection appears a promising alternative to 24-h [177Lu]Lu-PSMA SPECT/CT for treatment response assessment, with improved patient convenience.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Swiha M, Pathmanandavel S, Papa N, et al. Comparison of Posttherapy 4- and 24-Hour [177Lu]Lu-PSMA SPECT/CT and Pretherapy PSMA PET/CT in Assessment of Disease in Men with Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2024. PMID: 39477497. doi:10.2967/jnumed.124.267606

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。